Samenvatting
This study demonstrates that both the clinical sensitivity and specificity of the Cervista HPV HR test for high-risk human papillomavirus (HPV) detection are not inferior to those of the Hybrid Capture 2 (HC2) test. The intra- and interlaboratory reproducibilities of Cervista were 92.0% (kappa, 0.83) and 90.4% (kappa, 0.80), respectively. The Cervista HPV HR test fulfills all the international HPV test requirements for cervical primary screening purposes.
Originele taal-2 | English |
---|---|
Pagina's (van-tot) | 4391-4393 |
Aantal pagina's | 3 |
Tijdschrift | Journal of Clinical Microbiology |
Volume | 52 |
Nummer van het tijdschrift | 12 |
DOI's | |
Status | Published - dec.-2014 |